Revelation Biosciences, Inc. (REVB)
| Market Cap | 3.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -120,254 |
| Shares Out | 1.63M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | 7.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,130 |
| Open | 2.140 |
| Previous Close | 2.070 |
| Day's Range | 2.040 - 2.140 |
| 52-Week Range | 1.780 - 39.000 |
| Beta | 0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 20, 2024 |
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment o... [Read more]
Financial Performance
Financial StatementsNews
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of ...
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of t...
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of ...
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a limited number of accepted abstract authors, t...
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of...
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement a 1-for-30 ...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immun...
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company's Gemini...
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based t...
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based t...
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc.
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based t...
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split ...